Kardigan, Inc. is a clinical-stage precision therapeutics company. It is developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Its pipeline of products includes Danicamtiv, Ataciguat and Tonlamarsen. Danicamtiv is an investigational oral cardiac atrial and ventricular myosin activator for the treatment of genetic dilated cardiomyopathy caused by pathogenic variants in myosin heavy chain 7 (MYH7) and titin, the common sarcomeric gene variants. Ataciguat is an investigational oral, once-daily soluble guanylate cyclase activator aimed at slowing the progression of calcific aortic valve stenosis in patients with moderate diseases. Tonlamarsen is an investigational liver-directed antisense oligonucleotide administered once-monthly via subcutaneous injection, targeting hepatic angiotensinogen for the management of blood pressure in acute severe hypertension post-hospitalization. Prolaio is a clinical intelligence platform.
Símbolo de cotizaciónKARD
Nombre de la empresaKardigan Inc
Fecha de salida a bolsaJun 18, 2026
Director ejecutivoGianakakos (Tassos Anastasios)
Número de empleados420
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 18
Dirección506 Carnegie Center Drive, Suite 201
CiudadPRINCETON JUNCTION
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal08540
Teléfono14155733220
Sitio Webhttp://www.kardigan.bio
Símbolo de cotizaciónKARD
Fecha de salida a bolsaJun 18, 2026
Director ejecutivoGianakakos (Tassos Anastasios)